Abstract
Antibiotic resistant infections affect millions of people each year, killing tens of thousands of people in the United States alone. The rate at which bacteria are becoming resistant is surpassing the rate that novel antibiotics are able to be produced, and thus it is becoming clear that new targets are necessary. One possible target of inhibition is ATP synthase, which has the potential to kill both Gram-negative and Gram-positive bacteria. Bedaquiline (BDQ), the first new FDA approved drug to treat Mycobacterium tuberculosis in decades, is an ATP synthase inhibitor, the discovery of which opens the door to a large quantity of potential antibiotics. Herein, the synthesis of diarylquinoline benzyl thiol with amino acid substituents, analogues based off of BDQ, was developed to selectively inhibit ATP synthase of Pseudomonas aeruginosa, a highly infectious Gram-negative pathogen.
How to Cite
Jackson, D. O., (2022) “Synthesis of diarylquinoline thiols for use as selective Pseudomonas aeruginosa ATP synthase inhibitors”, Capstone, The UNC Asheville Journal of Undergraduate Scholarship 35(1).
6
Views
1
Downloads